Receptor Binding Domain | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

17,876 results for “Receptor Binding Domain”

Trials

View all 9049 →

Active, not recruiting

Neonatal SARS-CoV-2 Anti-spike Protein Receptor-binding Domain Antibodies at Delivery

58 participants · First posted Oct 4, 2022

COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores

35 participants · First posted Feb 15, 2022

The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores

9 participants · First posted Sep 27, 2021

Drugs

View all 1481 →

PHH-1V81

Nanobodies specific for the receptor binding domain (RBD) of SARS-CoV-2 spike

Investigational

Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine

Organizations

View all 71 →

Domain Therapeutics SA

France

Arvinas Estrogen Receptor, Inc.

United States

Arvinas Androgen Receptor, Inc.

United States

News

View all 7275 →

Mosaic-8b Nanoparticle Vaccine Shows Promise Against Sarbecovirus Variants

Machine Learning Identifies Serological Predictors of COVID-19 Outcomes

KP.2 COVID-19 Vaccines Demonstrate Sustained 70% Effectiveness Over 12 Months in Major US Study

Page 1 of 1788